Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s10157-016-1313-5 http://scihub22266oqcxt.onion/10.1007/s10157-016-1313-5 C5388729!5388729!27422620     free     free     free       Clin+Exp+Nephrol 2017 ; 21 (2): 193-202 Nephropedia Template TP {{tp|p=27422620|t=2017. Rituximab for nephrotic syndrome in children |pdf=|usr=}}{{27422620}} gab.com Text Rituximab for nephrotic syndrome in children JO: Clin Exp Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=27422620 #FOAvip Idiopathic nephrotic syndrome is the most common chronic glomerular disease in children. At least 20 % of children with this syndrome show frequent relapses and/or steroid dependence during or after immunosuppressive therapies, a condition defined as complicated frequently relapsing/steroid-dependent nephrotic syndrome (FRNS/SDNS). Approximately 1?3 % of children with idiopathic nephrotic syndrome are resistant to steroids and all immunosuppressive agents, a condition defined as refractory steroid-resistant nephrotic syndrome (SRNS); these SRNS children have a high risk of end-stage renal failure. Rituximab, a chimeric anti-CD20 monoclonal antibody, has been shown to be effective for patients with complicated FRNS/SDNS and refractory SRNS. This review describes the recent results of rituximab treatment applied to pediatric nephrotic syndrome, as well as those of our recent study, a multicenter, double-blind, randomized, placebo-controlled trial of rituximab for childhood-onset complicated FRNS/SDNS (RCRNS01). The overall efficacy and safety of rituximab for this disease are discussed. Twit Text FOAVip Rituximab for nephrotic syndrome in children ????Clin Exp Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=27422620 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27422620 #FOAvip English Wikipedia <ref>{{Cite pmid|27422620}}</ref> Rituximab for nephrotic syndrome in children #MMPMID27422620 Iijima K; Sako M; Nozu K Clin Exp Nephrol 2017[]; 21 (2): 193-202 PMID27422620show ga Idiopathic nephrotic syndrome is the most common chronic glomerular disease in children. At least 20 % of children with this syndrome show frequent relapses and/or steroid dependence during or after immunosuppressive therapies, a condition defined as complicated frequently relapsing/steroid-dependent nephrotic syndrome (FRNS/SDNS). Approximately 1?3 % of children with idiopathic nephrotic syndrome are resistant to steroids and all immunosuppressive agents, a condition defined as refractory steroid-resistant nephrotic syndrome (SRNS); these SRNS children have a high risk of end-stage renal failure. Rituximab, a chimeric anti-CD20 monoclonal antibody, has been shown to be effective for patients with complicated FRNS/SDNS and refractory SRNS. This review describes the recent results of rituximab treatment applied to pediatric nephrotic syndrome, as well as those of our recent study, a multicenter, double-blind, randomized, placebo-controlled trial of rituximab for childhood-onset complicated FRNS/SDNS (RCRNS01). The overall efficacy and safety of rituximab for this disease are discussed. äRituximab for nephrotic syndrome in children (epmc).pdf DeepDyve Pubget Overpricing